Actively Recruiting
Association of Middle Molecules Clearance With HDF Volume
Led by East and North Hertfordshire NHS Trust · Updated on 2024-07-23
400
Participants Needed
1
Research Sites
75 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
HDF is a dialysis technique which involves diffusion and convection. HDF with high convection volume has consistently shown to improve survival in dialysis patients in number of robust RCTs. The precise reason of this survival benefit remains unclear. The investigators hypothesize that this survival benefit with high volume HDF is related to enhanced middle molecule clearance and hemodynamic stability. However, this relationship has not been studied so far. This observational study is aimed to understand the relationship between HDF convection volume with middle molecules (Beta 2-Microglobulin) clearance during HDF. Exploring the relationship of HDF volume with middle molecules clearance has significant clinical ramifications. Only a minority of patients are able to achieve target convection volume. Understanding these relationships can rationalize the HDF prescription from convection volume-based prescription to β2-Microglobulin clearance-based prescription which may be applicable to wider range of patients. The relationship between pre-dialysis β2-Microglobulin levels and RKF offers the prospect of dispensing with pre- and post-dialysis urea and creatinine measurements and interdialytic urine collections, currently necessary for estimating RKF, thus simplifying its estimation. β2-Microglobulin reduction ratio and its component pre and post-dialysis β2-Microglobulin levels could therefore provide a composite estimate of small and middle molecule clearance and RKF.
CONDITIONS
Official Title
Association of Middle Molecules Clearance With HDF Volume
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or above
- Ability to give informed consent
- End stage renal failure treated by dialysis for at least 3 months
- Established on haemodiafiltration for more than 4 weeks
- Prognosis more than 6 months as assessed by the principal investigator
You will not qualify if you...
- Age less than 18 years
- Inability to give informed consent
- Prognosis less than 6 months as assessed by the principal investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
East and North Hertfordshire NHS Trust
Stevenage, Hertfordshire, United Kingdom, SG1 4AB
Actively Recruiting
Research Team
U
Usama A Butt, MBBS,MRCP
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here